Presentation: Human primary B lymphocytes for the rapid high throughput discovery of native therapeutic monoclonal antibodies

NB

Developing therapeutic monoclonal antibodies and ADC's is a key focus of the pharmaceutical industry's R&D. The European Antibody Congress 2012 bought together senior level executives and opinion leaders from around the globe to further their knowledge and engage in discussion on a variety of topics relating to mAbs, ADC's and bispecifics. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Dr Nicola Beltraminelli, Director of Antibody Discovery Platform, Vivalis, ‘Human primary B lymphocytes for the rapid high throughput discovery of native therapeutic monoclonal antibodies'.

 

This presentation focuses on:

· Native monoclonal antibodies directly isolated from carefully selected human donors constitute an ideal "ready-to-use" pharmacological format but their discovery was until now limited by the lack of potent technologies and easy access to human donors

· The VIVA|SCREEN technology was developed that allows the rapid single cell screening and selective retrieval from large populations of healthy or diseased human donors of individual B lymphocytes secreting highly biologically active antibodies

· This technology was successfully applied for a series of targets and allowed the cloning of a large number of potent native human antibodies, including antibodies produced by B lymphocytes present only at a very low frequency in human PBMCs (<1/100,000,000)

 

Download this presentation here.

 

Are you interested in learning more and engaging in discussion on mAbs, ADC's, bispecifics and antibody biosimilars? Do you want to hear the most recent updates on mAbs/ADC's at the clinical stage? Do you want to network with senior executives and opinion leaders from truly international antibody pioneers? Take a look at the European Antibody Congress 2013.

Vivalis will once again be presenting at the European Antibody Congress in 2013.

Leave a Reply

Your email address will not be published. Required fields are marked *